Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
1995-03-15
2011-11-01
Woodward, Cherie M (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S141100, C436S512000, C530S387100, C530S388100, C530S866000
Reexamination Certificate
active
08048414
ABSTRACT:
F(ab) fragments are isolated from an antibody containing source by contacting the antibody containing source with a papain-polyacrylamide matrix to produce F(ab) and F(c) fragments which are then passed through an antigen-polyacrylamide gel capable of attracting the F(ab) fragments. F(ab)2fragments are obtained by contacting the antibody containing source with a pepsin-polyacrylamide matrix to produce F(ab)2and F(c) fragments which are then passed through an antigen-polyacrylamide gel capable of attracting the F(ab)2fragments. IgG antibodies are obtained by passing an antibody containing source through an antigen-polyacrylamide gel. These processes can be used to purify a wide variety of antibodies which can be used as therapeutic agents and as diagnostic agents. Antivenins produced by these processes have substantially reduced foreign protein levels and hence are less likely to produce immunogenic reactions. Bulk, unprocessed antibody sources may be utilized and, for reasons of process simplification, are preferred.
REFERENCES:
patent: 4012502 (1977-03-01), Philpot
patent: 4529700 (1985-07-01), Gratzner et al.
patent: 4595654 (1986-06-01), Reckel et al.
patent: 4742159 (1988-05-01), Batz et al.
patent: 4849352 (1989-07-01), Sullivan et al.
patent: 5256409 (1993-10-01), Blincko
Stanworth et al., Section B, Chapter 6, pp. 6.14-6.24 From Handbook of Exp. Imm, DW Weir ed., Blackwell Scientific, 1979.
Bernfeld et al., Science, vol. 142, 678-679, 1963.
Smith et al., Clin Exp. Immunol., vol. 36, 384-396, 1979.
Goding, Section 4.5.2, p. 130-132, from Monoclonal Antibodies: Principles and Practices, Acad Press, 1986.
Coulter et al., J. Imm Methods, 59, 199-203, 1983.
Sullivan, Med. Toxicol., 1:47-60, 1986.
Sullivan et al., Vet. Hum. Toxicol., 26:400, Abstract A-9, 1984.
Stedman's Medical Dictionary, 23rd Edition, Pub. Williams and Wilkins Co., p. 94. (1976).
Sullivan et al Proc West Pharmacol Sor 25: 185-92 1982.
Carrsi et al. Naturz 221: 385-6 1969.
Martinez-Hernandez J Histochem & Cytochem 23: 146-148 (1976).
McGuire et al., Equine IgG and IgG(T) antibodies: Dependence of Precipitability on Both Antigen and Antibody Structure, Molecular Immunology 16:787-790 (1979).
Karlson-Stuber et al., Antivenom Treatment inVipera berusEnvenoming-Report of 30 cases, J Internal Medicine 235:57-61 (1994).
Kukongviriyapan et al., Some Parameters of Affinity Chromatography in the Purification of Antibody AgainstNaja Naja Siamensis, J Immunological Methods 49:97-104 (1982).
Russell et al., Preparation of a new antivenin by affinity chromatography, Am J Trop Med Hyg 34:141-50 (1985).
Martinez-Hernandez et al., Acrylamide affinity chromatography for immunohistochemistry. Purification of specific antibodies, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 23:146-8 (1975).
Jeter et al., Anaphylaxis in guinea pigs challenged with antivenin preparations. Toxicon 21:729-30 (1983).
Calderon-Aranda et al., Pharmacokinetics of the toxic fraction ofCentruroides limpidus limpidusvenom in experimentally envenomed rabbits and effects of immunotherapy with specific F(ab')2, Toxicon 37:771-782 (1999).
Ismail et al., Pharmacokinetics of 125I-labelled IgG, F(ab')2 and Fab fractions of scorpion and snake antivenins: merits and potential for therapeutic use, Toxicon 36:1523-1528 (1998).
Coulter et al., Enzyme Immunoassay for the rapid clinical identification of snake venom, The Medical Journal of Australia 1:433-435 (1980).
Grandgeorge et al., Preparation of improved F(ab')2 antivenoms. An example: new polyvalent anti-European vipers (equine), Toxicon 34:148(1996).
Guidlolin et al., Polyvalent horse F(Ab')2 snake antivenom: development of process to produce polyvalent horse F(Ab')2 antibodies anti-african snake venom, African J Biotechnology 9:2446-2455 (2010).
A Comparison ofCrotalinae(Pit Viper) Equine Immune F(ab)2 Antivenom (Anavip) and Crotalidae Polyvalent Immune Fab, Ovine Antivenom (CroFab) in the Treatment of Pit Viper Envenomation, http://www.bioportfolio.com/resources/trial/78581/A-Comparison-Of-Crotalinae-pit-Viper-Equine-Immune-F-ab-2-Antivenom.html, (Last Accessed Nov. 2010).
de Vries, Isolation of snake venom toxins and study of their mechanism of action (1970). http://www.dtic.mil/cgi-bin/GetTRDoc?Location=U2&doc=GetTRDoc.pdf&AD=AD0728504.
Leon et al., Comparative study on the ability of Igg and Fab sheep antivenoms to neutralize local hemorrhage, edema and myonecrosis induced byBothrops asper(terciopelo) snake venom, Toxicon 38:233-244(2000).
Orphan Drug, http://en.wikepedia.org/wiki/Orphan—drug, (Last Accessed Nov. 2010).
Otero-Patino et al., A randomized, blinded, comparative trial of one pepsin-digested and two whole IgG antivenoms forBothropssnake bite in Uraba,Columbia, Am J Trop Med Hyg 58:183-189 (1998).
Riviere et al., Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits toward an optimization of antivenom therapy, J Pharm and Exp Therap 281:1-8 (1997).
Saetang et al., Quantitative comparison on the refinement of horse antivenom by salt fractionation and ion-exchange chromatography, J Chromatog 700:233-239 (1997).
Sanofi Who Proposal, Application for inclusion of Equine F(ab')2 antivenoms in the WHO model list for essential medicines, http://archives.who.int/eml/expcom/expcom15/applications
ewmed/equine/antivenoms.pdf, (Last Accessed Nov. 2010).
Sullivan et al., Protection againstCrotalusvenom lethality by monovlaent, polyclonal F(ab) fragments: in search of a better snake trap, Vet Hum Toxicolgy 26:400 (1984) (Received National Library of Medicine Sep. 25, 1984).
Sutherland et al., A study of the major Australian snake venoms in the monkey (Macaca fascicularis) I. the movement of injected venom, methods which retard this movement, and the response to antivenoms, Pathology 13:13-27 (1981).
Amatoxin, http://en.wikipedia.org/wiki/Amatoxin Oct. 5, 2010.
[No Author Listed] CroFab® Crotalidae Polyvalent Immune Fab (Ovine). Highlights of Prescribing Information. Sep. 2010. 16 pages.
[No Author Listed] WHO Guidelines for Production, Control and Regulation of Snake Antivenom Immunoglobulins. World Health Organization. 2010. 114 pages.
[No Author Listed] WHO Progress in the characterization of venoms and standardization of antivenoms. WHO Offset Publication No. 58. World Health Organization. Geneva. 1981. 44 pages.
Agner et al., Hemocytes of schistosome-resistant and—susceptibleBiomphalaria glabratarecognize different antigens on the surface ofSchistosoma mansonisporocysts. J Parasitol. Apr. 1995;81(2):179-86.
Alape-Girón et al., A comparison of in vitro methods for assessing the potency of therapeutic antisera against the venom of the coral snakeMicrurus nigrocinctus. Toxicon. Apr. 1997;35(4):573-81.
Almeida et al., Involvement of the major glycoprotein (gp43) ofParacoccidioides brasiliensisin attachment to macrophages. Med Mycol. Dec. 1998;36(6):405-11.
Amuy et al., Development of immunoassays for determination of circulating venom antigens during envenomations by coral snakes (Micrurusspecies). Toxicon. Nov. 1997;35(11):1605-16.
Angulo et al., Effects of bleeding in horses immunized with snake venoms for antivenom production. Rev Biol Trop. 1997;45(3):1215-21.
Backovic et al., Efficient method for production of high yields of Fab fragments inDrosophilaS2 cells. Protein Eng Des Sel. Apr. 2010;23(4):169-74. Epub Jan. 24, 2010.
Balthasar et al., Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. J Pharm Sci. Oct. 1996;85(10):1035-43.
Bar-Or et al., Neutralization of croatalidae venom induced platelet aggregation by affinity chromatography isolated IgG toCrotalus viridis hellerivenom. J Toxicol Clin Toxicol. Jul. 1984;22(1):1-9.
Bessen et al., Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes. J Immunol. Aug. 15, 1990;145(4):1251-6.
Bizzini et al., Defining a r
Russell Findlay E.
Sullivan John B.
BTG International Inc.
Wolf Greenfield & Sacks P.C.
Woodward Cherie M
LandOfFree
Antivenom composition containing Fab fragments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antivenom composition containing Fab fragments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antivenom composition containing Fab fragments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4282029